2018 had been one of the biggest years for initial public offerings (IPOs) in the biotechnology industry, and China’s pharma valley, Zhangjiang National Innovation Zone, has witnessed a boom in the listing of bio-pharmaceutical enterprises in Hong Kong.

According to the recent data released by Ipreo, a financial data provider, a total of 33 enterprises in the global biotechnology sector raised more than $100 million through IPOs in 2018, including three in Zhangjiang, namely Beigene, Junshi Biosciences and Hua Medicine.

Among those, Beigene ranked top with its IPO financing reaching $900 million.

The Novartis Shanghai in Zhangjiang is the company's third largest R&D center in the world. [Photo/WeChat account: zhangjiangfabu]

The biomedical industry is one of the leading industries in Zhangjiang. And Zhangjiang is one of the regions with the most concentrated pharmaceutical research institutions, the strongest R&D capability, the most abundant achievements in new drugs and the most complete innovation ecology in China.

Zhangjiang made remarkable achievements in bio-medicine in 2018, especially in innovation.

With the ascending biomedical industry, Zhangjiang, which has gathered high-end global innovation resources, will bring its original innovations to the world to benefit more people. 

The R&D center of Shanghai Jiao Tong University is under construction in Zhangjiang National Innovation Zone. It will open in 2020. [Photo/WeChat account: zhangjiangfabu]